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We have investigated whether DNA regions present in lhc rabbit whey acidic protein (WAP) promoter/S' flankingsqucnce could polentiallyconfix. 
in viva, high level expression of reparlcr genes. Transgcnic mice were generated expressing a varianl of human a,-anrhrypsin. which has inhibitory 
activity against plasma kallikrein under lhc control or a 17.6 kbp DNA fraymcnt located upstream or the rabbi1 WAP gene. Up IO IO mg/ml oI’ 
aclive and correctly processed recombinant protein were detected in mouse milk, thus suggesting that lhc far upsiream DNA sequences from the 
rabbit WAP gene mighi be useful for engineering elIicicnt prolein production in the mammary glands of lransgcnic animals. 
Rabbii: WAP gent; a,-Anlhrypsin: Transgenic mouse: Milk; Plasma kallikrcin 
1. INTRODUCTlON 2. MATERIALS AND METHODS 
Whey acidic protein (WAP) is the principal whey 
protein found in mouse, rat and rabbit milk [l-4]. WAP 
-~jn:hesis complex. being regulated by g!ucocorticoids 
and pyolactin as well as by cell-ceii ~IIL! se!!--rxtrarellr~- 
lar matrix interactions, thus indicating that efficient ex- 
pression is achieved only when a correctly organised 
cellular structure similar to that found in the mammary 
gland is maintained [5]. The promoter and upstream 
sequences (2.6 kbp) of the murine WAP gene have been 
used to direct the tissue and developmental expression 
of several foreign proteins in the milk of transgenic mice 
[6-91, the expression levels of the chimcric transgenes 
being relatively low with respect to those of endogenous 
milk proteins or to exogeneous transgenic mouse or rat 
WAP [IO-121. This suggests that regulatory DNA se- 
quences 11ot included in the transgenic construct might 
play a role in order to attain high levels of expression 
of the exogenous gene. 
Previous in vitro studies [131 had identified important 
regulatory elements within a 6.3 kbp fragment located 
upstream of the rabbit WAP gene. Here we report the 
generation of transgenic mice containing a fusion trans- 
gene in which the gene coding for a modified version of 
human a,-antitrygsin (a,AT) was ligated to a 17.6 kbp 
fragment of the rabbit S’ flanking region WAP gene. 
Corrcspundertce nr/drcss: A. Pavirnni, TRANSGENE %A., I I rue de 
Molshcim, 67082 Strasbourg Cedex, France. Fax: (33) 88 22 58 07. 
2. I. Adorcrids 
In ihe ELISA assay goat an&human al AT antisera and pcroni- 
dasc-linked a&goat antibodies were rrom Cappel (Malvern. PA. 
USA). Human plasma a,AT was obtained from Calbiochcm (Mcu- 
don. France). RID plaits were purchased from Behring (Marburg. 
Gcrzxzy). Hllman plasma kallikrcin and the chromogenic substrate. 
S-2302, were from Kabi Vitrum (Stockholm. S~~diii;; f)zz.idz~~- 
coupled immunoglobulin G fraction or goat anli-human-cr,AT anti- 
bodies was oblaincd from Cappel. All other reagents were ofonalyti- 
cal grade. 
2.2. DNA cotmwct 
The genomic sequences corresponding 10 Ihc human o,AT gcnc and 
Ihe rabbi1 WAP promoter region [ 141 were isolated as separdlc lambda 
EMBL3 or Charon 4A clones from a human lymphocyte DNA library 
[IS] and from a rabbit liver library (prepared by T. Maniatis). rcspcc 
lively. Using site-directed mutigencsis amino acid residues 357 (Pro) 
and 358 (MCI) 01’ human u,A?’ were changed imo Ala and Arg rcsi- 
dues, respectively. thereby pcneraling the gcnomic a,AT (Ala-357. 
Arg-358) variant [l6.17] which was subsequenily introduced down- 
stream or a 17.6 kbp rabbit WAP promoler fragment (er&cercd 
Hirtdlli site[l3,14])cloncd in thevcclorpPolyIll-I* [18].Theresul~ing 
plasmid was named pTGIGO6, and the transgcnc (Fig. I) could bc 
isolated from the procaryotic scquenccs by a Noit restriction digest. 
2.3. Gctfc,rurion of trurrsgertk faire 
Transgcnic mice were generated according to [I91 using C57BY 
6xSfL hybrid crosses and idcnlificd by lnil DNA analysis on Soulhcrn 
blots. 
2.4. Cuttretmttiott of rr,AT (Ah-357. A@581 in Iuctcrsmnt ur~d 
Mood .wfIlll? 
Milk samples were collected at day I3 after parturition from anes- 
thesizcd mice previously injcclcd with 0.05 U of oxylocin 10 stimulotc 
milk lel-down [20]. Mouse milk was diluted (l:S) in distilled water. fal 
was removed after centrifugalion and uliquots wcrc stored frozm at 
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Fig. I. Schematic representation f the injected fusion trunsgcne de- 
rived from pTG 1606 after digestion with Null. Filled and open boxes 
represent exons (roman numbers) and introns of the variant a,AT 
gene, respectively. Solid line indicates 5’ flanking regions (up to 
- 17,600 bp from the CAP site, arrowed) of the rabbit WAP gene as 
well as 3’ flanking regions of the human o,AT gene (approximately 
3,000 hp). 
-70°C until use. Blood was collected from tails. allowed to coagulate 
at room temperature and the serum stored frozen at -7OOC until USC. 
The quantification of a,AT (Ala-357. Arg-358) was done by ELISA 
1211. 
3S. d!%crrupirorelic profit 
SDS-PAGE was performed using 10% (w/v) acylamide [22]. Pro- 
tein bands were stained with Coomassic blue R-250 and immunoblot- 
ting was performed according to [33], Detection was performed using 
horseradish pcroxidase and 4-chloro-I-naphtol, 
Anti-kallikrein activity was measured as described [ 171 at a human 
plnsma kallikrein concentration of 7 nivli. a,AY (Ala-357, Arg-358), 
either puritied from ,!Z coli or present in mouse lactoserum. was added 
to the reaction mixture at a concentration of 39.1 or 59.8 n?vl, respec- 
tively. The reaction was started by adding the chromogenic substrate. 
SX!Q&. t.2.2 !&to!* tenee~+XiQ& of j-7 ;cr?&. Z?,r+T {2&X? k~~33Zj 
concentrations were determined by radial immunodin’usion (RID) 
according to the manuPxturers recommendations. Measurements 
were done on a 8451 diode array spcctrophotometer (Hewlett-Pack- 
ard, Waldbronn, FRG). Second order association constants A,,, were 
determined from the measured pseudo&s1 order rntc constants, I?. 
as described [I71 using a minimal excess of five-fold of inhibitor over 
proteasc. Data wcrc analyzed by linear regression ofthc semi-lognrith- 
mic plot (correlation coeflicients between 0.994 and 0.907). 
3. RESULTS 
3.1. E.spression qf trunsgemk a/AT (Ab-357, Arg-3.58) 
The transgcne construct includes 176 kbp of the rab- 
bit WAP promoter with the transcription start site fused 
to the gene coding for the (Ala-357, Arg-358) variant of 
the human a,AT (Fig. I) in which the substrate specific- 
ity of q-antitrypsin was changed from neutrophil elas- 
tase to plasma kallikrein [lG]. 
Nine transgenic founders were identified (5 females 
and 4 males). A high degree of cannibalism of the moth- 
ers towardsitheir litters was observed. Eventually four 
out of five rpothers were successfully capable of lactat- 
ing their pups. a,AT (Ala-357, &g-3%) antigen levels 
were measured in both lactosera nd blood sera at day 
11-I 3 after litter birth (Table I), showing elevated secre- 
tion of the human protein in both fluids (up to 6 mg/ml 
and 700 pg/rnl in milk and serum, respectively, for fe- 
male 105). No direct correlation between copy number 
of the integrated transgene and a,AT (Ala-357, Arg 
358) levels could be made (not shown). Moreover blood 
serum levels ranging up to 35 ~~$rnl were found in trans- 
genie males. 
Transgenic male 106 produced eight Fl transgenics 
of which two were females (106 142 and 106 I 45). a,AT 
(Ala-357, Arp358) levels in lactoserum and blood 
serum reached up to 10.5 mg/ml and 220 ,ug/ml, respec- 
tively. Levels in male descendants were similar to those 
of the founder, 106 A time-course of a,AT (Ala-357, 
Arg-358) levels in blood serum from two females (not 
shown) demonstrated basal concentrations of around 
hn-~~,~~rn.l.Wi~~~~~91,~~~~~l~2+, day l.B a.%%: 
parturition and a slow decrease to normal levels after 
113 days post litter birth. 
QAT (Ala-357, Arg-358) secreted into the milk of 
transgenic mouse 1OG I 45 was first analyzed by SDS- 
Table I 
Antigen levels of cr,AT (Ala-337, Arg-358) &/ml) in lactosera nd blood sera obtained from FO and FI transgenic donors 
FO Lacroserum Blood serum Fl Lactoserum Blood serum 
44 9 6,000 310 106142 9 9.250 150 
77 9 370 ND 106145 9 7.000- 10.500 I50-230 
IO5 9 6,000 700 106 147 d 20 
I12 9 1,400 23 lO6149c? 13.5 
I24 P NDD NDD 
IOB d 35 
I:! 6 22 
13s s 14 
133 d ND 
_.<-1- 
Samples wcrc collected between day I l-13 postpartum after oxytocin injection. Values from mouse I06 I 45 are representative of two samplings. 
Antigen levels in control normal mice were cl0 @ml. ND, not detectable; NDD, not determined (mouse I24 failed repeatedly to give birth or 
clsc cannibalised her litter). 
266 
Volume 305, number 3 FEBS LETTERS 
A B 
- -. 
July 1992 
29 
‘70 
* 74 
7 2 3 4 5 7234567 
Fig, 2. (A) SDS-PAGE under denaturing and reducing conditions of lactoserum from a normal mouse (lane I), lactoserum from transgcnic mouse 
106 I 45 (lane 2), purified a,AT from human plasma (lane 3), molecular weight markers (lane 4) and purified o,AT (Ala-357, Arg-358) from a 
recombinant strtain of E. co/i (lane 5). (B) Immunoblol al’tcr SDS-PAGE of lactoserum from transgcnic mouse 1OG I 45 (lancs 1-3; 200. lo0 and 
50 ng of a,AT (Ala-357. Arg-3%) as determined by RID) and of a,AT purified from human plasma (lanes 5-7; 200. 150 and 100 ng by RID). 
Lactoserum from control normal mice was negative. Molecular weight markers in kDa arc indicated on the figure margins. 
PAGE under denaturing and reducing conditions, 
which showed that it was the major protein in lactose- 
rum (Fig. 2A, lane 2). The recombinant molecule had 
electrophoretic mobility identical to a,AT isolated from 
human plasma (Fig. 2A, lane 3), indicating that it was 
glycosylated. a,AT (Ala-357, Arg-358) purified from a 
recombinant strain of E. coli which was lacking carbo- 
hydrates [173 had a faster electrophoretic profile (Fig. 
2A, lane 5). Scanning of lane 2 (Fig. 2A) of the Coomas- 
sic blue-stained gel showed that approximately 35% of 
all the proteins in lactoserum of the transgenic mouse 
corresponded to the recombinant molecule. Lactoserum 
from the transgenic mouse was subsequently analyzed 
by immunoblotting after SDS-PAGE and compared to 
alAT from human plasma (Fig. 2B), A major im- 
munoreactive band migrating with an apparent molecu- 
lar weight identical to that of the human molecule was 
present. However, in lactoserum a second protein band 
with slightly reduced electrophoretic mobility stained 
less intensely (Fig. 2B, lanes l-3). Lactoserum from the 
milk of normal mice did not respond upon immunoblot- 
ting (not shown). 
Inhibitory activity of a,AT (Ala-357, Arg-358) in lac- 
toserum from mouse 106 I 45 was determined by meas- 
uring the second order association rate constant (k,,J 
with human plasma kallikrein in comparison to the pu- 
Table II 
Second order association rate constants in X-’ :< s-’ 
Lactoserum (mouse 106 1 45) I.64 x 10s 
Q;,AT (Ala-357. Arg-358) (E. co/i) 1.7L x 10s 
Lactoserum (normal mouse) no inhibition 
rified inhibitor obtained from E. co/i. Lactoserum from 
normal mice served as a negative control. Table II sum- 
marizes the results showing that a,AT (Ala-357, Arg 
358) in lactoserum of the transgenic mouse or purified 
from recombinant E. co/i had identical association rate 
constants with human plasma kallikrein, thus corre- 
sponding well with previously determined values [17]. 
Lactoserum from normal mice did not show any inhibi- 
tion of plasma kallikrein in this assay. 
4. DISCUSSION 
This study represents a first step towards the under- 
standing of the complex regulation of the rabbit WAP 
promoter in viva. 
Our data suggest hat DNA sequences located up to 
17.6 kbp upstream of the rabbit WAP gene are respon- 
sible for the high levels of reporter human protein pres- 
ent in the milk of tsansgenic mice. The promoter/S 
flanking sequence mployed herein contains hormone- 
responsive lements which were previously charactcr- 
ized using rabbit primary mammary cells [13] and which 
might be responsible for such elevate levels. However, 
further upstream regions (between - 17.6 and -6.3 kbp) 
may be implicated. Alternatively, the particular human 
gene emplcyed here or regulation at the post-transcrip- 
tional level might be responsible for such elevate xpres- 
sion. We are at present investigating these hypotheses. 
High levels of a,AT (Ala-357, Arg-358) were found 
in blood serum of transgenic females and males, being 
in direct correlation with the lactating period in the 
females. It is conceivable that the regulatory DNA se- 
quences present in this particular construct confer tis- 
sue-specificity which is not restricted to the mammary 
gland alone. Preliminary data on WAP-regulated trans- 
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gene expression support this concept. In any case such 
high circulating levels might result in toxicity and ;1c* 
count therefore for the observed cannibalism. 
Recombinant a,AT (Ala-357, Arg-358) comprised 
about 35% of total protein in mouse lactoserum under- 
scoring its efficient expression and secretion and proved 
to be as efficient in inhibition of human plasma kal- 
likrein as the unglycosylated counterpart purified from 
a recombinant strain of E. cofi. A minor band recogni- 
sed as the a,AT variant migrated with a lower apparent 
molecular weight in lactoserum of a transgenic mouse. 
This might correspond to a degradation product of the 
recombinant protein presumably through cleavage in its 
exposed inhibitory loop or to a different glycosylated 
form. A similar observation was also reported in the 
case of human a,AT expressed in transgenic mouse milk 
[24] and may raise important questions concerning both 
stability (e.g. temperature, presence of proteases) and 
post-translational microheterogeneity of recombinant 
proteins in the milk of transgenic animals. 
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